Background: Deregulated Notch signaling due to mutation or overexpression of ligands and/or receptors is implicated in various human malignancies. c-Secretase inhibitors inhibit Notch signaling by preventing cleavage of transmembrane domain of Notch protein. LY3039478 is a novel, potent Notch inhibitor decreases Notch signaling and its downstream biologic effects. In this first-in-human study, we report the safety, pharmacokinetic (PK) profile, pharmacodynamic effects, and antitumor activity of LY3039478 in patients with advanced or metastatic cancer.
Introduction
The Notch signaling pathway plays an integral role in tissue development and homeostasis and involve the inhibition of apoptosis and the promotion of cell proliferation [1, 2] . Deregulated Notch signaling due to mutation or overexpression of ligands and/or receptors is implicated in a number of malignancies [3] [4] [5] . LY3039478 is an orally bioavailable potent Notch inhibitor that prevents release of the Notch intracellular domain (NICD) by inhibiting proteolytic activity of c-secretase complex and thereby decreasing Notch signaling and its downstream biologic effects. LY3039478 has been shown to inhibit Notch signaling in cell lines representing a number of different solid tumors and leukemia including T-cell acute lymphoblastic leukemia. In xenograft models, LY3039478 demonstrates significant activity against human ovary, colon, and non-small-cell lung cancers [6] .
Dosing regimen was established based on the schedule optimization studies in preclinical models (supplementary Figure S1 , available at Annals of Oncology online). Nonclinical toxicology studies in rats and dogs dosed thrice weekly (TIW) for 1 month have characterized the target tissues for toxicity that may be clinically relevant (data not shown). In nonclinical species, the gastrointestinal (GI) tract is the key target organ for toxicity, with some changes also observed in the reproductive systems. In the mouse GI system, administration of LY3039478 is associated with goblet cell hyperplasia and a mucoid enteropathy affecting the small and large intestine (supplementary Figure S2 , available at Annals of Oncology online). This reversible enteropathy is characterized by the development of nonformed or liquid mucoid feces.
In this phase I study, we have evaluated the safety, PK profile, pharmacodynamic effects, antitumor activity of LY3039478 in patients with advanced or metastatic cancer leading to the determination and confirmation of the recommended phase II dose.
Methods

Study design and treatment
This phase I, open-label, multicenter, nonrandomized, and doseescalation phase study enrolled 110 patients in 8 centers worldwide (ClinicalTrials.gov identified: NCT01695005). In part A, patients received increasing dose levels of oral LY3039478 (range 2.5-100 mg) TIW on a 28-day cycle. Dose-escalation was guided by safety assessments from days 1 through 28 of cycle 1 for patients in all. Part B cohort expansion began following an interim review of the data at the maximum tolerated dose (MTD). LY3039478 was administered until symptomatic or confirmed progressive disease, unacceptable toxicity, or other reasons for study drug discontinuation.
The primary objectives of this study were to determine and confirm the recommended phase II dose that may be safely administered to patients with advanced or metastatic cancer and secondary objectives were to characterize the safety, tolerability, PK parameters, and preliminary antitumor activity of LY3039478.
Patients
All patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1, adequate organ and hematologic functions. Part B patients had measurable disease or reliable biomarker. Efficacy assessments. Radiographic imaging was conducted approximately every 8 weeks. Depending on the histology, tumor responses were measured and recorded using the appropriate guidelines (RECIST 1.1) [7] by investigators.
Study assessments
Use of positron emission tomography (PET) scan to assess treatment effect of LY3039478 was optional. Partial metabolic response by PET scan was defined as a minimum of 15% in tumor 18 F-FDG SUV after 1 cycle of therapy, and >25% after more than one treatment cycle, according to PET response criteria of the European Organization for Research and Treatment of Cancer [8] .
PK assessments. LY3039478 plasma and urine concentrations were measured using validated LC/MS/MC methods.
Exploratory biomarker assessments. Gene expression: Skin biopsy samples collected before and after LY3039478 treatment were analyzed for changes in gene expression using a reverse transcriptase polymerase chain reaction (RT-PCR) method at Asuragen (Austin, TX) per standard protocol [9] . Eighteen Notch signaling genes were analyzed Plasma Ab levels were determined post-treatment on days 1 and 22 of cycle 1.
Immunohistochemistry: A total of 68 specimens were submitted containing sufficient tumor tissue for biomarker evaluation following review by a board-certified pathologist (G.J.O.) of a hematoxylin and eosin (H&E)-stained section of each sample (47 in part A and 21 in part B). Separate sections of the patient's tumor were assayed for the NICD specific for Notch 1, Notch 2, and Notch 3.
Results were interpreted and scored qualitatively by a board-certified pathologist (G.J.O.) based on the immunoreactivity for the NICD fragment observed in the specimen using a scale of 0 (no staining) to 3þ (intense specific nuclear staining).
Results
Patient characteristics
In total, 110 patients with advanced or metastatic cancer were treated with LY3039478 monotherapy between 31 October 2012 and 15 July 2016. The median age of patients was 58 years and majority had ECOG PS 1 (71%). Patients were heavily pretreated; 33% received !5 prior systemic therapy regimens. The most common tumor types are represented in Table 1 
Safety and tolerability
During the dose-escalation portion of the study (part A), 5 of the 55 patients (9%) experienced DLTs (supplementary Table S1 , available at Annals of Oncology online). The DLTs of grade 4 thrombocytopenia with bleeding were experienced by 1 patient each in cohort 4 (20 mg), and cohort 5 (30 mg). Grade 4 thrombocytopenia without bleeding was observed in 1 patient in cohort 7 (60 mg). DLTs of grade 3 colitis (1 patient) and grade 3 nausea (not manageable with medical treatment) associated with grade 3 fatigue (1 patient) were experienced in cohort 9 (100 mg). In addition, 1 patient in cohort 7 (60 mg) experienced a DLET of grade 3 colitis during cycle 2, and 1 patient in cohort 9 (100 mg) experienced a DLET of grade 3 fatigue during cycle 4. The MTD was determined to be 75 mg TIW. Diarrhea (n ¼ 25, 45%), and vomiting (n ¼ 25, 45%) were the most commonly reported TEAEs possibly related to LY3039478 (supplementary Table S2 , available at Annals of Oncology online). Median duration of treatment of patients in part A was 2 cycles (range <1-18 cycles).
During the dose confirmation portion of the study (part B), additional review of the safety data from part B (25 patients) revealed that the 75-mg dose was not well tolerated, leading to dose reductions in $30% of patients mainly due to GI toxicity. Most of related AEs occurred in cycle 1 or 2.
In the dose confirmation phase, 25 patients received LY3039478 monotherapy at 75 mg, and 30 patients received LY3039478 monotherapy at 50 mg. The most commonly reported TEAEs possibly related to LY3039478 were diarrhea (n ¼ 33, 60%), vomiting (n ¼ 26, 47%), and nausea (n ¼ 24, 44%) ( Table 2 ). With the reduction of the MTD of LY3039478 from 75 to 50 mg TIW, a lower incidence of diarrhea was observed (76% of patients versus 47% of patients). At the MTD of 50 mg TIW the majority of the events were mild to moderate in severity, with few patients experiencing grade 3/4 events. Median duration of treatment of patients in part B was 2 cycles (range <1-13 cycles). A total of 19 patients in part B experienced serious adverse events (SAEs) that were considered possibly related to the study drug by the investigator (supplementary Table S3 , available at Annals of Oncology online).
A total of 17 deaths have been reported on or within 30 days of study treatment. Fifteen patients died because of disease progression and two patients died due to an AE (one patient received the 60-mg dose and one patient received the 100-mg dose, both due to nondrug-related sepsis).
Pharmacokinetics
Plasma exposure increased approximately dose proportionally (supplementary Tables S4 and S5 , available at Annals of Oncology online). Maximum concentrations were achieved $2 h postdose. The half-life is $6 h; no accumulation was noted with TIW dosing. Exposures for doses !20 mg were in line or exceeded exposures tested in xenografts models (supplementary Figure S1 , available at Annals of Oncology online). 
Biomarker and pharmacodynamic analyses
The effect of LY3039478 on plasma Ab concentrations followed an approximate dose-dependent trend, with $80% reductions in plasma Ab observed from 45 to 100 mg (supplementary Figure  S4 , available at Annals of Oncology online). Additionally, expression of Notch-regulated genes was assessed to monitor pharmacodynamic effect of LY3039478 on skin. Skin samples were collected before and after $6 h of LY3039478 treatment. The panel consisted of Notch-regulated genes, of which inhibition !50% was observed for hairy and enhancer of split-1 (Hes1), cyclin D1 (CCND1), and Notch-regulated ankyrin repeat (NRARP) (Figure 1 ). The effect of LY3039478 on levels of other genes was weak to none (Hes2, Hes4, Hes5, HeyL, and MYC). The maximum PD effect was observed at 45 mg and was maintained throughout the dose-escalation, suggesting the 45 mg dose may be the minimal biologic efficacious dose.
Antitumor activity
In part A, PR was observed in one patient with breast cancer (ER/ PRþ HER2À and FBXW7 mutation), with duration of response of 9.5 months. Seventeen (31%) patients had a Best response of stable disease is observed in 17 (31%) and 19 (35%) patients of part A and part B, respectively, of which sustained duration >6 months was observed in 5 patients in each part.
In part B, no patients had CR or PR. The change in tumor size for patients who had measurable disease and at least 1 post treatment radiological assessment (39 patients in part A and 41 patients in part B) is shown in Figure 2A . This summary is consistent with the summary of ORR as reported by the investigators (1 patient in part B had a 100% decrease in tumor size for their target lesion, but progressive disease due to appearance of new lesions). Clinical benefit rates were 11% in part A and 9% in part B. In addition, we did observe tumor necrosis in some patients ( Figure 2B ).
Across both dose escalation and dose expansion study parts for which patients with advanced cancers of multiple histologies were enrolled, the estimated median time to disease progression or death was 1.68 months (95% CI 1.45-2.04) and 1.77 months (95% CI 1.68-3.29), respectively.
Thus far, emerging unvalidated results for 18 F-FDG PET/computed tomography (PET-CT) assessment included two metabolic responders in patients with adenoid cystic carcinoma and testis cancer (metastatic malignant Sertoli-Leydig tumor). In part A, 1 (chondrosarcoma) of the 10 patients with pre-and posttreatment PET-CT assessment had unconfirmed partial metabolic response, and 22 of 55 patients in part B with pre-and post-treatment PET-CT assessment, of which 4 patients (breast cancer, glioblastoma, rectal cancer, and adenoid cystic carcinoma) had unconfirmed partial metabolic response (supplementary Figure S5 , available at Annals of Oncology online). The patient with breast cancer response did have Notch 1 ICD positive status while Notch 2 and 3 were negative.
Pre-and post-treatment biopsies were obtained from a patient with leiomyosarcoma receiving 100 mg LY3039478 (Figure 3) . Histologically, there is extensive necrosis of the tumor on the post-treatment biopsy. These changes were seen in association with a rapid tumor necrosis after LY3039478 monotherapy identified on a CT scan obtained on cycle 1 day 4 of treatment. Immunohistochemistry carried out on pre-and post-treatment biopsies shows this leiomyosarcoma was positive for activated Notch 1 receptor.
Discussion
This report describes the first-in-human treatment with LY3039478, a highly potent and selective Notch inhibitor. We have established LY3039478 can be dosed safely on a TIW schedule. Five DLTs were identified, and the recommended phase dose was determined to be 75 mg TIW and then reduced to a dose of (7) 2 (7) 1 ( 50 mg TIW. GI toxicity (diarrhea and nausea) was the major toxicity observed in this study. These events were consistent with the previously reported clinical safety profile for Notch pathway inhibitors and are on target toxicities [10] [11] [12] [13] [14] [15] [16] [17] . With the reduction of the MTD of LY3039478 from 75 to 50 mg TIW in the dose confirmation phase, a lower incidence of diarrhea was observed, suggesting a positive effect on GI tolerance. The observed DLTs of thrombocytopenia during part A were not dose dependent and were not confirmed during part B. These cases of thrombocytopenia are likely confounded by the underlying patients' conditions. The PK parameters of LY3039478 increased in a doseproportional manner. Plasma Ab (a surrogate PD marker for Notch signaling following administration of a c-secretase inhibitor) [18] and Notch pathway gene expression measurements showed that maximal biomarker effects were obtained at $15-50 mg LY3039478. This substantial Notch pathway inhibition supports the use of the 50 mg TIW LY3039478.
Although the patient population was heterogeneous and heavily pretreated (33% of patients receiving LY3039478 monotherapy as sixth line or greater), 1 PR and 10 instances of prolonged stable disease were achieved. In addition, metabolic responses or tumor necrosis was observed in other patients. Of note, three patients with adenoid cystic carcinoma had a duration of treatment of 8.0 months, of which one was evaluable for immunohistochemistry and was Notch-1þ. This result correlates with recent prevalence studies revealing adenoid cystic carcinomas have a high expression of Notch 1 receptor activation [19] .
Overall, single agent activity of LY3039478 and other notch inhibitors did show limited activity in unselected solid tumors [11, 13, 20] . Further exploration of potential predictive biomarkers such as NICD is warranted. Improvement of activity might be achieved by the combination with other agents. One ongoing study is exploring LY3039478 in combination with other anticancer agents (taladegib or abemaciclib or cisplatin/gemcitabine, or gemcitabine/carboplatin) in solid tumors [21] .
Another potential axis of development of Notch inhibitors are hematologic malignancies where Notch pathway can be a key a driver for the disease as lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL) [22] .
Finally, recently a study reported that c-secretase inhibition increases recognition of multiple myeloma by BCMA-specific chimeric antigen receptor modified T (CAR-T) cells. This has served as basis for the initiation of a trial combining BCMAspecific CAR-T cells [23] .
The results of this trial demonstrate the safety and preliminary antitumor activity of LY3039478 as a single agent. A major strength of the presented results is the clinical pharmacodynamic effect seen on Notch-targeted genes after treatment with LY3039478. This work supports the rational for targeting Notch signaling and further implicates aberrant Notch signaling in tumor physiology.
